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Dear Editor,
The article by Ertekin et al. published in Hepatitis 
Monthly indicates that a new hepatitis B virus (HBV) vac-
cine schedule should be created for children with celiac 
disease (CD), and the response of all children with CD 
to the HBV vaccine should be routinely investigated (1). 
The authors investigated a group of children with CD 
vaccinated against HBV and found that the anti-HBs ti-
ter was not detected in a signiﬁcant percentage (38.5%) 
of children. In addition, the clinical presentation of the 
disease and dietary compliance of the patients seemed 
to play a role in nonresponsiveness to the HBV vaccine. 
Therefore, the authors suggest a diﬀerent immunization 
schedule. Most studies indicate that major histocompat-
ibility complex (MHC) and human leukocyte II antigens 
(HLA-II) are responsible for nonresponsiveness to HBV 
vaccine (2-5). However, Nemes et al. (6) found that the 
percentage of seroconversion (95.5%) in a group of pa-
tients vaccinated after initiating dietary treatment was 
similar to that in healthy individuals, and overall, 36 out 
of 37 nonresponders consuming a controlled gluten-
free diet showed seroconversion after administering a 
booster dose of vaccine. This ﬁnding shows that HLA DQ 
alleles do not have a primary role in nonresponsiveness 
to HBV vaccine. The nature of protection aﬀorded by vac-
cination is complex and, although both humoral and cy-
totoxic T-cell responses play a role, long-term protection 
is dependent upon immunological memory. The general 
belief is that immunological memory persists for a long 
period after natural infection and administration of live 
vaccines. For many years, the response to HBV vaccina-
tion is determined by measuring the anti-HBs titer, and 
a patient with an anti-HBs level < 10 mIU/mL is consid-
ered to be a nonresponder. However, responsiveness to 
HBV vaccination is usually determined by testing within 
2–6 months after receiving the third dose of the vaccine. 
Thus, the nonresponsiveness to HBV vaccine might be 
secondary to the tendency of older individuals having a 
weaker response to the vaccine or not developing immu-
nity. In patients with anti-HBs level < 10 IU/L, a schedule 
for booster vaccinations should be proposed, but no con-
sensus has been achieved on the management of nonre-
sponders to date.
A high dose of HB vaccine is administered in healthy in-
dividuals, but this procedure is not uniformly successful 
(7). Recently, 90% seroconversion was observed in a pilot 
study in patients after administration of a booster dose 
of vaccine by the intradermal (ID) route (8). Large pro-
spective randomized studies are required to validate this 
procedure to improve the eﬃcacy and safety of the cur-
rent standard protocol. The mechanism of induction of 851
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immunogenicity via intradermal administration is not 
clearly established but may be related to the sequestra-
tion of the antigens in the dermis for a long time after in-
tradermal injection. The dermis contains large numbers 
of dendritic cells (the most potent antigen-presenting 
cells) that are important for the ID route of immuniza-
tion, and these cells are thought to induce cell-mediated 
immune responses, particularly CD4+ and CD8+ T-cell 
responses. In addition, dendritic cells enhance antibody 
production by B cells through eﬃcient induction of 
CD4+ T-cell modulation of B cells and thus a lower anti-
gen dose is required to produce an immune response.
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